CLAIMS

What is claimed is:

1. Use of patidegib or a pharmaceutically acceptable salt thereof, in the preparation of a topical medicament for the treatment and/or prevention of basal cell carcinoma lesions, in a subject in need thereof, wherein the subject must have a genetic mutation PTCH1 and suffers from Gorlin syndrome.

2. The use of claim 1, wherein the subject has at least 6 BCC lesions.

3. The use of claims 1 or 2, wherein the patidegib is in an amount of about 0.1% w/w to about 6% w/w.

4. The use of claim 3, wherein the patidegib is in an amount of 2%, 3% or 4% w/w.

5. The use of claim 4, wherein the patidegib is in an amount of 2% w/w.

6. The use of any one of claims 1-5, wherein the patidegib is formulated as a gel or a cream formulation.

7. The use of any one of claims 1-6, wherein the treatment of basal cell carcinoma results in a reduction of BBC lesion size or resolved BBC lesion over time.

8. The use of any one of claims 1-7, wherein the prevention of basal cell carcinoma lesions refers to preventing formation of new BCCs, or new surgically eligible BCCs.

9. The use of any one of claims 1-8, wherein the pharmaceutical composition is topically administered once daily, twice daily, trice daily, every other day, or three times a week.

10. The use of claim 9, wherein the pharmaceutical composition is topically administered for a period of about 3 months, 6 months, about 9 months, about 12 months, more than 12 months, or for a lifetime.

11. The use of any one of claims 1-10, wherein the subject does not develop drug resistance.

12. The use of any one of claims 1-11, wherein following a discontinuation period of administration during the treatment, the drug efficacy is not affected.

13. The use of any one of claims 1-12, wherein the use resolves and or reduces the size of surgically eligible BCCs.